B. Pitcher

发表

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

E. Mardis, C. Perou, M. Ellis, 2016, npj Breast Cancer.

CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

M. Czuczman, B. Cheson, Sin-Ho Jung, 2014, Cancer Immunology Research.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

E Mardis, E. Mardis, C. Fan, 2014, British Journal of Cancer.

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

J. Friedberg, J. Leonard, B. Cheson, 2015 .

Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)

L. V. van't Veer, B. Pitcher, W. Barry, 2018, Clinical Cancer Research.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Scott E. Smith, Sonali M. Smith, J. Leonard, 2017, The Lancet. Haematology.

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Sonali M. Smith, J. Leonard, B. Cheson, 2014 .

Impact of compliance with an enhanced recovery after surgery pathway on patient outcomes in open gynecologic surgery

B. Pitcher, P. Ramirez, M. Iniesta, 2019, International Journal of Gynecological Cancer.

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

M. Czuczman, J. Leonard, B. Cheson, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response by Activating Unlicensed NK Cells CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma

M. Czuczman, B. Cheson, B. Pitcher, 2014 .

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.

J. Leonard, C. Flowers, T. Habermann, 2020, The Lancet. Haematology.

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Donald A. Berry, Mark T. W. Ebbert, Charles M. Perou, 2013, Breast Cancer Research and Treatment.

Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc

D. Berry, C. Perou, E. Winer, 2015 .

Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy

E. Mardis, C. Perou, E. Winer, 2012 .

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

D. Berry, E. Mardis, C. Fan, 2018, Clinical Cancer Research.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

D. Berry, C. Perou, E. Winer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhanced recovery for obese patients undergoing gynecologic cancer surgery

B. Pitcher, P. Ramirez, M. Iniesta, 2020, International Journal of Gynecological Cancer.

A Prospective Randomized Trial Comparing Liposomal Bupivacaine vs. Standard Bupivacaine Wound Infiltration in Open Gynecologic Surgery On An Enhanced Recovery Pathway.

B. Pitcher, M. Munsell, P. Ramirez, 2020, American journal of obstetrics and gynecology.

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

Scott E. Smith, Sonali M. Smith, M. Czuczman, 2015, Blood.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

J. Leonard, B. Cheson, B. Pitcher, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J. Friedberg, J. Leonard, B. Cheson, 2018, Blood.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

L. Staudt, W. Wilson, A. Zelenetz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

J. Leonard, B. Cheson, B. Pitcher, 2017 .

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Scott E. Smith, M. Czuczman, J. Leonard, 2018, Cancer medicine.

Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)

Scott E. Smith, M. Czuczman, J. Leonard, 2016 .

Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.

M. Czuczman, J. Leonard, B. Cheson, 2020, The American journal of surgical pathology.

Phase 2 multicentre study of single‐agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)

Sonali M. Smith, J. Leonard, B. Cheson, 2019, British journal of haematology.

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

H. Cohen, E. Winer, C. Hudis, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

A. LaCasce, B. Cheson, Sin-Ho Jung, 2015, Leukemia & lymphoma.

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)

H. Cohen, E. Winer, C. Hudis, 2017, Breast Cancer Research and Treatment.

Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).

H. Cohen, E. Winer, C. Hudis, 2014, Journal of oncology practice.

Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907

H. Cohen, E. Winer, C. Hudis, 2013, Breast Cancer Research and Treatment.

Open Versus Minimally Invasive Radical Trachelectomy in Early-Stage Cervical Cancer: International Radical Trachelectomy Assessment Study.

B. Pitcher, D. Cibula, C. Fotopoulou, 2021, American journal of obstetrics and gynecology.

Impact of implementation of an enhanced recovery program in gynecologic surgery on healthcare costs.

B. Pitcher, P. Ramirez, A. Guzman, 2020, American journal of obstetrics and gynecology.

Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

D. Berry, E. Mardis, C. Perou, 2015 .

Long‐term trajectories of self‐reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

H. Cohen, B. Pitcher, C. Isaacs, 2016, Cancer.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.

B. Pitcher, A. Sood, P. Ramirez, 2019, Gynecologic oncology.

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

J. Byrd, A. LaCasce, M. Czuczman, 2015 .

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Scott E. Smith, L. Staudt, W. Wilson, 2016 .

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).

H. Cohen, E. Winer, C. Hudis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

D. Berry, E. Mardis, C. Fan, 2018, Clinical Cancer Research.